Bintai Kinden picks IEC Properties to supply Covid-19 vaccine in Australia, NZ
KUALA LUMPUR: Bintai Kinden Corporation Bhd’s subsidiary has picked ASX-listed IEC Properties Pty Ltd as sole distributor for the Ii-Key-SARS-CoV-2 Covid-19 vaccine in Australia and New Zealand.
Bintai Healthcare Sdn Bhd had on Thursday signed an MoU with IEC – a unit of International Equities Corporation Ltd to further negotiate on the terms and conditions to grant IEC the exclusive distribution rights.
Recall that Bintai Healthcare was granted the exclusive rights from Generex Biotechnology Corporation and its subsidiary NuGenerex Immuco-Oncology Inc to distribute, sell and commercialise the Covid-19 vaccine in all Asean countries and also Timor-Leste.
Bintai Healthcare was also given the first right of refusal to distribute and market the vaccine within Australia, New Zealand and the global halal market.
Bintai Kinden managing director Ong Choon Lui described the collaboration with with International Equities as important milestone for its healthcare business segment.
“With this collaboration, we aim to supply Covid-19 vaccine in Australia and New Zealand through our partner (International Equities) which has the extensive reach in the said markets.
“This is indeed important for Bintai Kinden as Australia has a population of 25.5 million and New Zealand’s population is five million, ” he added.
Bintai Kinden’s core businesses are property development, tourism, hotel management, and others, which include real estate sales and management.